Researchers have discovered a new experimental drug that might be effective against a challenging type of bladder cancer called BCG-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC). This form of cancer is often difficult to treat and typically comes after traditional immunotherapy, like BCG (Bacillus Calmette-Guérin), doesn’t work.
The new treatment, named TAR-200, is being studied by Janssen Research & Development, which is part of Johnson & Johnson. Unlike traditional treatments that may require bladder removal surgery, TAR-200 offers a less invasive option.
TAR-200 is a small device that releases the chemotherapy drug gemcitabine directly into the bladder. It is inserted through an outpatient procedure that does not require anesthesia, allowing patients to receive treatment without the stress of a major surgery. After the device is placed, it gradually releases the medicine over several weeks.
Dr. Sia Daneshmand, who leads the study, highlighted that this new therapy could change how bladder cancer is treated, especially since options have been quite limited for patients so far. He noted that the drug is currently the most effective alternative for this common type of bladder cancer.
Bladder cancer ranks as the fourth most prevalent cancer in men and the eleventh in women. According to the Urology Care Foundation, NMIBC is located in the bladder’s inner lining. The high-risk type of this cancer has a higher chance of returning even after treatment. This study aims to provide new hope for patients whose cancer has come back despite standard therapies.
In many cases, the standard approach for these patients was surgery to remove the bladder, which can lead to significant health risks and affect quality of life. The new treatment could help some patients avoid this drastic measure.
The clinical trial involved patients who had high-risk NMIBC that didn’t respond to BCG. Different groups were tested with various combinations of treatments. One group received TAR-200 every three weeks for about six months, with follow-up treatments every three months for up to two years.
Among the 85 patients in this group, 82.4% showed no signs of cancer after treatment, with over half remaining cancer-free for a year, and many stayed cancer-free for more than two years after treatment.
Another group with a less aggressive form of early-stage bladder cancer also showed positive results, with a high percentage of patients able to retain their bladders.
While the early trial results are promising, researchers emphasize that further extended studies will be necessary before TAR-200 could become a standard treatment. They noted that the current study has limitations, including a lack of traditional comparison to other treatments and a relatively small patient group.
Overall, this research highlights a hopeful advancement in bladder cancer treatment, which could greatly improve patients’ lives in the future.
